Literature DB >> 26968698

Normalization of cardiac substrate utilization and left ventricular hypertrophy precede functional recovery in heart failure regression.

Nikole J Byrne1, Jody Levasseur1, Miranda M Sung1, Grant Masson1, Jamie Boisvenue1, Martin E Young2, Jason R B Dyck3.   

Abstract

AIMS: Impaired cardiac substrate metabolism plays an important role in heart failure (HF) pathogenesis. Since many of these metabolic changes occur at the transcriptional level of metabolic enzymes, it is possible that this loss of metabolic flexibility is permanent and thus contributes to worsening cardiac function and/or prevents the full regression of HF upon treatment. However, despite the importance of cardiac energetics in HF, it remains unclear whether these metabolic changes can be normalized. In the current study, we investigated whether a reversal of an elevated aortic afterload in mice with severe HF would result in the recovery of cardiac function, substrate metabolism, and transcriptional reprogramming as well as determined the temporal relationship of these changes. METHODS AND
RESULTS: Male C57Bl/6 mice were subjected to either Sham or transverse aortic constriction (TAC) surgery to induce HF. After HF development, mice with severe HF (% ejection fraction < 30) underwent a second surgery to remove the aortic constriction (debanding, DB). Three weeks following DB, there was a near complete recovery of systolic and diastolic function, and gene expression of several markers for hypertrophy/HF were returned to values observed in healthy controls. Interestingly, pressure-overload-induced left ventricular hypertrophy (LVH) and cardiac substrate metabolism were restored at 1-week post-DB, which preceded functional recovery.
CONCLUSIONS: The regression of severe HF is associated with early and dramatic improvements in cardiac energy metabolism and LVH normalization that precede restored cardiac function, suggesting that metabolic and structural improvements may be critical determinants for functional recovery. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2016. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Cardiac hypertrophy; Heart failure regression; Metabolism; Remodelling

Mesh:

Year:  2016        PMID: 26968698      PMCID: PMC4836630          DOI: 10.1093/cvr/cvw051

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  56 in total

1.  Resveratrol treatment of mice with pressure-overload-induced heart failure improves diastolic function and cardiac energy metabolism.

Authors:  Miranda M Sung; Subhash K Das; Jody Levasseur; Nikole J Byrne; David Fung; Ty T Kim; Grant Masson; Jamie Boisvenue; Carrie-Lynn Soltys; Gavin Y Oudit; Jason R B Dyck
Journal:  Circ Heart Fail       Date:  2014-11-13       Impact factor: 8.790

Review 2.  Calorie restriction and resveratrol in cardiovascular health and disease.

Authors:  Vernon W Dolinsky; Jason R B Dyck
Journal:  Biochim Biophys Acta       Date:  2011-07-01

Review 3.  Global signatures of protein and mRNA expression levels.

Authors:  Raquel de Sousa Abreu; Luiz O Penalva; Edward M Marcotte; Christine Vogel
Journal:  Mol Biosyst       Date:  2009-10-01

4.  Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction.

Authors:  JiuChang Zhong; Ratnadeep Basu; Danny Guo; Fung L Chow; Simon Byrns; Manfred Schuster; Hans Loibner; Xiu-hua Wang; Josef M Penninger; Zamaneh Kassiri; Gavin Y Oudit
Journal:  Circulation       Date:  2010-08-02       Impact factor: 29.690

5.  Myocardial ATGL overexpression decreases the reliance on fatty acid oxidation and protects against pressure overload-induced cardiac dysfunction.

Authors:  Petra C Kienesberger; Thomas Pulinilkunnil; Miranda M Y Sung; Jeevan Nagendran; Guenter Haemmerle; Erin E Kershaw; Martin E Young; Peter E Light; Gavin Y Oudit; Rudolf Zechner; Jason R B Dyck
Journal:  Mol Cell Biol       Date:  2011-12-12       Impact factor: 4.272

Review 6.  Genetics of energetics: transcriptional responses in cardiac metabolism.

Authors:  H Taegtmeyer
Journal:  Ann Biomed Eng       Date:  2000-08       Impact factor: 3.934

7.  Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy.

Authors:  S Neubauer; M Horn; M Cramer; K Harre; J B Newell; W Peters; T Pabst; G Ertl; D Hahn; J S Ingwall; K Kochsiek
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

8.  Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure.

Authors:  Biao Lei; Vincenzo Lionetti; Martin E Young; Margaret P Chandler; Chiara d'Agostino; Elaine Kang; Martin Altarejos; Ken Matsuo; Thomas H Hintze; William C Stanley; Fabio A Recchia
Journal:  J Mol Cell Cardiol       Date:  2004-04       Impact factor: 5.000

9.  PGC-1β deficiency accelerates the transition to heart failure in pressure overload hypertrophy.

Authors:  Christian Riehle; Adam R Wende; Vlad G Zaha; Karla Maria Pires; Benjamin Wayment; Curtis Olsen; Heiko Bugger; Jonathan Buchanan; Xiaohui Wang; Annie Bello Moreira; Torsten Doenst; Gema Medina-Gomez; Sheldon E Litwin; Christopher J Lelliott; Antonio Vidal-Puig; E Dale Abel
Journal:  Circ Res       Date:  2011-07-28       Impact factor: 17.367

10.  Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003.

Authors:  Hoe-Nam Leong; Brenda Ang; Arul Earnest; Cindy Teoh; Wei Xu; Yee-Sin Leo
Journal:  Trop Med Int Health       Date:  2004-08       Impact factor: 2.622

View more
  12 in total

1.  Metabolic remodeling of substrate utilization during heart failure progression.

Authors:  Liang Chen; Jiangping Song; Shengshou Hu
Journal:  Heart Fail Rev       Date:  2019-01       Impact factor: 4.214

2.  Regression from pathological hypertrophy in mice is sexually dimorphic and stimulus specific.

Authors:  Deanna L Muehleman; Claudia Crocini; Alison R Swearingen; Christopher D Ozeroff; Leslie A Leinwand
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-03-18       Impact factor: 4.733

Review 3.  Loss of Metabolic Flexibility in the Failing Heart.

Authors:  Qutuba G Karwi; Golam M Uddin; Kim L Ho; Gary D Lopaschuk
Journal:  Front Cardiovasc Med       Date:  2018-06-06

Review 4.  Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology.

Authors:  Jolanda van der Velden; Carlo G Tocchetti; Gilda Varricchi; Anna Bianco; Vasco Sequeira; Denise Hilfiker-Kleiner; Nazha Hamdani; Adelino F Leite-Moreira; Manuel Mayr; Ines Falcão-Pires; Thomas Thum; Dana K Dawson; Jean-Luc Balligand; Stephane Heymans
Journal:  Cardiovasc Res       Date:  2018-08-01       Impact factor: 10.787

Review 5.  Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure.

Authors:  Nikole J Byrne; Nirmal Parajuli; Jody L Levasseur; Jamie Boisvenue; Donna L Beker; Grant Masson; Paul W M Fedak; Subodh Verma; Jason R B Dyck
Journal:  JACC Basic Transl Sci       Date:  2017-08-04

6.  Distinct Phenotypes Induced by Three Degrees of Transverse Aortic Constriction in Mice.

Authors:  Daniel A Richards; Mark J Aronovitz; Timothy D Calamaras; Kelly Tam; Gregory L Martin; Peiwen Liu; Heather K Bowditch; Phyllis Zhang; Gordon S Huggins; Robert M Blanton
Journal:  Sci Rep       Date:  2019-04-10       Impact factor: 4.379

7.  Small animal models of heart failure.

Authors:  Christian Riehle; Johann Bauersachs
Journal:  Cardiovasc Res       Date:  2019-11-01       Impact factor: 10.787

8.  Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.

Authors:  Xueling Li; Qin Zhu; Qingcheng Wang; Qinggang Zhang; Yaru Zheng; Lihong Wang; Qinyang Jin
Journal:  Cardiovasc Drugs Ther       Date:  2020-10       Impact factor: 3.727

9.  The Degree of Cardiac Remodelling before Overload Relief Triggers Different Transcriptome and miRome Signatures during Reverse Remodelling (RR)-Molecular Signature Differ with the Extent of RR.

Authors:  Patrícia G Rodrigues; Daniela Miranda-Silva; Xidan Li; Cláudia Sousa-Mendes; Ricardo Martins-Ferreira; Zaher Elbeck; Adelino F Leite-Moreira; Ralph Knöll; Inês Falcão-Pires
Journal:  Int J Mol Sci       Date:  2020-12-18       Impact factor: 5.923

10.  Left ventricular response in the transition from hypertrophy to failure recapitulates distinct roles of Akt, β-arrestin-2, and CaMKII in mice with aortic regurgitation.

Authors:  Jian Wu; Jieyun You; Xiaoyan Wang; Shijun Wang; Jiayuan Huang; Qihai Xie; Baoyong Gong; Zhiwen Ding; Yong Ye; Cong Wang; Le Kang; Ran Xu; Yang Li; Ruizhen Chen; Aijun Sun; Xiangdong Yang; Hong Jiang; Fenghua Yang; Peter H Backx; Junbo Ge; Yunzeng Zou
Journal:  Ann Transl Med       Date:  2020-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.